Ryosuke Okamura

Ryosuke Okamura

Auto-generated profile, based on publicly available information

Ryosuke Okamura

Department of Surgery, Kyoto University Hospital, Kyoto, Japan

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2019 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
JSJason Keith Sicklick
Jason Keith Sicklick
SKShumei Kato
Shumei Kato
RORyosuke Okamura
Ryosuke Okamura
MSMaria Schwaederle
Maria Schwaederle
MHMichael E. Hahn
Michael E. Hahn
RKRazelle Kurzrock
Razelle Kurzrock

1 November 2018 in JCO Precision Oncology
Verified
Journal Article
Closed access
RORyosuke Okamura
Ryosuke Okamura
ABAmélie Boichard
Amélie Boichard
SKShumei Kato
Shumei Kato
JSJason K. Sicklick
Jason K. Sicklick
LBLyudmila Bazhenova
Lyudmila Bazhenova
RKRazelle Kurzrock
Razelle Kurzrock
Purpose: Fusions that involve neurotrophic-tropomyosin receptor kinase ( NTRK) genes are known drivers of oncogenesis. Therapies that target these ultra-rare, constitutionally active NTRK fusions have been remarkably effective. Herein, we analyze the prevalence of the full array of NTRK alterations—fusions, mutations, copy number alterations, and increased transcript expression—in diverse adult and pediatric tumor types to understand the landscape of NTRK aberrations in cancer. Methods: We assessed 13,467 samples available from The Cancer Genome Atlas (adult tumors) and the St Jude PeCan database (pediatric tumors) for the prevalence of NTRK fusions, as well as associated genomic and transcriptomic co-aberrations in different tumor types. Results: NTRK fusions were observed in 0.31% of adult tumors and in 0.34% of pediatric tumors. The most common gene partners were NTRK3 (0.16% of adult tumors) followed by NTRK1 (0.14% of pediatric tumors). NTRK fusions were found more commonly in pediatric melanoma (11.1% of samples), pediatric glioma (3.97%), and adult thyroid cancers (2.34%). Additional genomic and transcriptomic NTRK alterations—mutation, amplification, and mRNA overexpression—occurred in 14.2% of samples, whereas the frequency of alterations that implicated NTRK ligands and the NTRK co-receptor (p75NTR) ranged from 3.8% to 5.4%. Among 31 adult samples carrying NTRK fusions, co-alterations occurred often and usually involved the downstream phosphoinositide-3-kinase signaling pathway, cell-cycle machinery, other tyrosine-kinase receptors, and mitogen-activated protein kinase signals. Conclusion: Whereas NTRK fusions are exceedingly rare, other NTRK abnormalities affect 14% of patients with cancer. Affecting these alterations has not yet been achievable in cancer. Genomic co-alterations occur frequently with NTRK fusions, but it is not known if co-targeting them can attenuate primary or secondary resistance to NTRK inhibitors.

2 October 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
SKShumei Kato
Shumei Kato
KKKi Hwan Kim
Ki Hwan Kim
HLHyo Jeong Lim
Hyo Jeong Lim
ABAmelie Boichard
Amelie Boichard
MNMina Nikanjam
Mina Nikanjam
RKRazelle Kurzrock
Razelle Kurzrock
Next-generation sequencing (NGS) can identify novel cancer targets. However, interpreting the molecular findings and accessing drugs/clinical trials is challenging. Furthermore, many tumors show resistance to monotherapies. To implement a precision strategy, we initiated a multidisciplinary (basic/translational/clinical investigators, bioinformaticians, geneticists, and physicians from multiple specialties) molecular tumor board (MTB), which included a project manager to facilitate obtaining clinical-grade biomarkers (blood/tissue NGS, specific immunohistochemistry/RNA expression including for immune-biomarkers, per physician discretion) and medication-acquisition specialists/clinical trial coordinators/navigators to assist with medication access. The MTB comprehensively reviewed patient characteristics to develop N-of-One treatments implemented by the treating physician’s direction under the auspices of a master protocol. Overall, 265/429 therapy-evaluable patients (62%) were matched to ≥1 recommended drug. Eighty-six patients (20%) matched to all drugs recommended by MTB, including combinatorial approaches, while 38% received physician’s choice regimen, generally with unmatched approach/low degree of matching. Our results show that patients who receive MTB-recommended regimens (versus physician choice) have significantly longer progression-free (PFS) and overall survival (OS), and are better matched to therapy. High (≥50%) versus low (<50%) Matching Score therapy (roughly reflecting therapy matched to ≥50% versus <50% of alterations) independently correlates with longer PFS (hazard ratio [HR], 0.63; 95% confidence interval [CI], 0.50–0.80;P < 0.001) and OS (HR, 0.67; 95% CI, 0.50–0.90;P = 0.007) and higher stable disease ≥6 months/partial/complete remission rate (52.1% versus 30.4%P < 0.001) (all multivariate). In conclusion, patients who receive MTB-based therapy are better matched to their genomic alterations, and the degree of matching is an independent predictor of improved oncologic outcomes including survival.

27 February 2020 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
RORyosuke Okamura
Ryosuke Okamura
SKShumei Kato
Shumei Kato
SLSuzanna Lee
Suzanna Lee
RJRebecca E Jimenez
Rebecca E Jimenez
JSJason Keith Sicklick
Jason Keith Sicklick
RKRazelle Kurzrock
Razelle Kurzrock
Background: Several cancer types harbor alterations in the gene encoding AT-Rich Interactive Domain-containing protein 1A (ARID1A), but there are no approved therapies to address these alterations. Recent studies have shown that ARID1A deficiency compromises mismatch repair proteins. Herein, we analyzed 3403 patients who had tumor tissue next-generation sequencing. Findings: Among nine cancer subtypes with >5% prevalence of ARID1A alterations, microsatellite instability-high as well as high tumor mutational burden was significantly more frequent in ARID1A-altered versus ARID1A wild-type tumors (20% vs 0.9%, p<0.001; and 26% vs 8.4%, p<0.001, respectively). Median progression-free survival (PFS) after checkpoint blockade immunotherapy was significantly longer in the patients with ARID1A-altered tumors (n=46) than in those with ARID1A wild-type tumors (n=329) (11 months vs 4 months, p=0.006). Also, multivariate analysis showed that ARID1A alterations predicted longer PFS after checkpoint blockade (HR (95% CI), 0.61 (0.39 to 0.94), p=0.02) and this result was independent of microsatellite instability or mutational burden; median overall survival time was also longer in ARID1A-altered versus wild-type tumors (31 months vs 20 months), but did not reach statistical significance (p=0.13). Conclusions: Our findings suggest that ARID1A alterations merit further exploration as a novel biomarker correlating with better outcomes after checkpoint blockade immunotherapy.

13 December 2018 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
SKShumei Kato
Shumei Kato
RORyosuke Okamura
Ryosuke Okamura
JBJoel M. Baumgartner
Joel M. Baumgartner
HPHitendra Patel
Hitendra Patel
LLLawrence Leichman
Lawrence Leichman
RKRazelle Kurzrock
Razelle Kurzrock
Purpose: Esophageal, gastro-esophageal junction and gastric adenocarcinoma (herein gastroesophageal adenocarcinomas) are associated with poor prognosis and limited systemic treatment options. To further understand the genomic landscape of gastroesophageal cancers and its clinical correlations, circulating tumor DNA (ctDNA) from patients' plasma was evaluated using next-generation sequencing (NGS). Methods: We analyzed genomic alterations of 55 patients (mostly advanced disease; nine, surgically resectable) with gastroesophageal adenocarcinomas using clinical-grade NGS performed on plasma-derived ctDNA (54-73 gene panel). The test detects single nucleotide variants, as well as copy number amplifications, fusions and indels in selected genes. Results: Seventy-six percent of patients (42/55) had ≥1 genomic alteration (including variants of unknown significance [VUSs]) and 69.1% (38/55) had ≥1 characterized alteration (excluding VUSs). The median number of alterations per patient was 2 (range, 0-15). TP53 (50.9%, 28/55), PIK3CA (16.4%, 9/55), ERBB2 (14.5%, 8/55) and KRAS (14.5%, 8/55) genes were most frequently affected characterized alterations. Thirty-one patients also had tissue NGS. Concordance between tissue and ctDNA ranged from 61.3% (TP53 alterations) to 87.1% (KRAS alterations). ERBB2 alterations were significantly associated with poor overall survival (HR: 14.06, 95% CI: 2.44 - 81.03, P=0.003 multivariate analysis). Among patients with ≥1 alteration, no two patients had identical molecular portfolios. All patients with ≥1 characterized alteration had theoretically targetable alterations by an FDA-approved agent (on- or off-label). Illustrative case treated with cognate agent is presented. Conclusions: Evaluation of ctDNA by NGS among gastroesophageal adenocarcinoma patients is feasible. Patients harbored heterogeneous patterns of genomics, with most having alterations that are potentially pharmacologically tractable.

1 August 2018 in Annals of Surgery
Verified
Journal Article
Open access
KHKoy Hid
Koy Hid
RORyosuke Okamura
Ryosuke Okamura
YSYoshiharu Sakai
Yoshiharu Sakai
TKTsuyoshi Konishi
Tsuyoshi Konishi
TATomonori Akagi
Tomonori Akagi
MWMasahiko Watanabe
Masahiko Watanabe
Background: Laparoscopic surgery for rectal cancer is widely performed all over the world and several randomized controlled trials have been reported. However, the usefulness of laparoscopic surgery compared with open surgery has not been demonstrated sufficiently, especially for the low rectal area. Objective: The aim of this study was to investigate the hypothesis that laparoscopic primary tumor resection is safe and effective when compared with the open approach for locally advanced low rectal cancer. Patients and Methods: Data from patients with clinical stage II to III low rectal cancer below the peritoneal reflection were collected and analyzed. The operations were performed from 2010 to 2011. Short-term outcomes and long-term prognosis were analyzed with propensity score matching. Results: Of 1608 cases collated from 69 institutes, 1500 cases were eligible for analysis. The cases were matched into 482 laparoscopic and 482 open cases. The mean height of the tumor from the anal verge was 4.6 cm. Preoperative treatment was performed in 35% of the patients. The conversion rate from laparoscopic to open surgery was 5.2%. Estimated blood loss during laparoscopic surgery was significantly less than that during open surgery (90 vs 625 mL, P < 0.001). Overall, the occurrence of complications after laparoscopic surgeries was less than that after open surgeries (30.3% vs 39.2%, P = 0.005). Three-year overall survival rates were 89.9% [95% confidence interval (95% CI) 86.7–92.4] and 90.4% (95% CI 87.4–92.8) in the laparoscopic and open groups, respectively, and no significant difference was seen between the 2 groups. No significant difference was observed in recurrence-free survival (RFS) between the 2 groups (3-year RFS: 70.9%, 68.4 to 74.2 vs 71.8%, 67.5 to 75.7). Conclusion: Laparoscopic surgery could be considered as a treatment option for advanced, low rectal cancer below the peritoneal reflection, based on the short-term and long-term results of this large cohort study (UMIN-ID: UMIN000013919).